Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.

Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR; Palivizumab Long-Term Respiratory Outcomes Study Group.

J Allergy Clin Immunol. 2010 Aug;126(2):256-62. doi: 10.1016/j.jaci.2010.05.026. Epub 2010 Jul 10.

PMID:
20624638
2.

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H.

Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1. Review.

3.

Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.

Kim S, Jang JE, Yu JR, Chang J.

Vaccine. 2010 May 14;28(22):3801-8. doi: 10.1016/j.vaccine.2010.03.032. Epub 2010 Mar 31.

PMID:
20362203
4.

A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus.

Fu YH, He JS, Wang XB, Zheng XX, Wu Q, Xie C, Zhang M, Wei W, Tang Q, Song JD, Qu JG, Hong T.

Biochem Biophys Res Commun. 2010 Apr 23;395(1):87-92. doi: 10.1016/j.bbrc.2010.03.144. Epub 2010 Mar 27.

PMID:
20350532
5.

Respiratory syncytial virus market.

Storey S.

Nat Rev Drug Discov. 2010 Jan;9(1):15-6. doi: 10.1038/nrd3075. No abstract available.

PMID:
20043025
6.

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.

Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA; Motavizumab Study Group.

Pediatrics. 2010 Jan;125(1):e35-51. doi: 10.1542/peds.2008-1036. Epub 2009 Dec 14.

PMID:
20008423
7.

Research priorities for health of people with disabilities: an expert opinion exercise.

Tomlinson M, Swartz L, Officer A, Chan KY, Rudan I, Saxena S.

Lancet. 2009 Nov 28;374(9704):1857-62. doi: 10.1016/S0140-6736(09)61910-3.

PMID:
19944866
8.

Respiratory syncytial virus vaccine development.

Murata Y.

Clin Lab Med. 2009 Dec;29(4):725-39. doi: 10.1016/j.cll.2009.07.004. Review.

9.

Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG.

J Virol. 2010 Jan;84(2):1110-23. doi: 10.1128/JVI.01709-09. Epub 2009 Nov 4.

10.

Setting priorities for global mental health research.

Tomlinson M, Rudan I, Saxena S, Swartz L, Tsai AC, Patel V.

Bull World Health Organ. 2009 Jun;87(6):438-46.

11.

Challenges in developing a pediatric RSV vaccine.

Schickli JH, Dubovsky F, Tang RS.

Hum Vaccin. 2009 Sep;5(9):582-91. Epub 2009 Sep 28. Review.

PMID:
19556888
12.

The complex challenge of setting priorities in health research investments.

Rudan I.

Indian J Med Res. 2009 Apr;129(4):351-3. No abstract available.

PMID:
19535827
13.

Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.

Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G.

Pediatr Infect Dis J. 2009 Jul;28(7):655-8. doi: 10.1097/INF.0b013e318199c3b1.

PMID:
19483659
14.

Setting research priorities to reduce global mortality from childhood diarrhoea by 2015.

Fontaine O, Kosek M, Bhatnagar S, Boschi-Pinto C, Chan KY, Duggan C, Martinez H, Ribeiro H, Rollins NC, Salam MA, Santosham M, Snyder JD, Tsai AC, Vargas B, Rudan I.

PLoS Med. 2009 Mar 10;6(3):e41. doi: 10.1371/journal.pmed.1000041. No abstract available.

15.

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, Portner A, Hurwitz JL.

Vaccine. 2009 Mar 13;27(12):1848-57. doi: 10.1016/j.vaccine.2009.01.041. Epub 2009 Feb 4.

16.

Respiratory syncytial virus: back to basics.

Glezen WP.

J Allergy Clin Immunol. 2009 Feb;123(2):404-5. doi: 10.1016/j.jaci.2008.11.033. Epub 2009 Jan 3. No abstract available.

PMID:
19121859
17.

Research priorities to reduce global mortality from newborn infections by 2015.

Bahl R, Martines J, Ali N, Bhan MK, Carlo W, Chan KY, Darmstadt GL, Hamer DH, Lawn JE, McMillan DD, Mohan P, Paul V, Tsai AC, Victora CG, Weber MW, Zaidi AK, Rudan I.

Pediatr Infect Dis J. 2009 Jan;28(1 Suppl):S43-8. doi: 10.1097/INF.0b013e31819588d7.

PMID:
19106763
18.

Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze.

Stensballe LG, Ravn H, Kristensen K, Agerskov K, Meakins T, Aaby P, Simões EA.

J Allergy Clin Immunol. 2009 Feb;123(2):398-403. doi: 10.1016/j.jaci.2008.10.043. Epub 2008 Dec 19.

PMID:
19101023
19.

Setting priorities in global child health research investments: guidelines for implementation of CHNRI method.

Rudan I, Gibson JL, Ameratunga S, El Arifeen S, Bhutta ZA, Black M, Black RE, Brown KH, Campbell H, Carneiro I, Chan KY, Chandramohan D, Chopra M, Cousens S, Darmstadt GL, Meeks Gardner J, Hess SY, Hyder AA, Kapiriri L, Kosek M, Lanata CF, Lansang MA, Lawn J, Tomlinson M, Tsai AC, Webster J; Child Health and Nutrition Research Initiative.

Croat Med J. 2008 Dec;49(6):720-33.

20.

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.

Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, Reisinger K, Chandler P, Hilty M, Walker RE, Gomez MM, Losonsky GA.

Vaccine. 2008 Nov 25;26(50):6373-82. doi: 10.1016/j.vaccine.2008.09.018. Epub 2008 Sep 24.

PMID:
18822334

Supplemental Content

Support Center